BofA upgraded Doximity (DOCS) to Buy from Neutral with a price target of $82, up from $75. The company’s shift from direct-to-consumer to healthcare professional is driving momentum into 2026, the analyst tells investors in a research note. The firm says the FDA’s recent reforms to direct-to-consumer advertising are adding friction, with pharmaceutical manufacturers beginning to shift spend away from the channel and toward the healthcare providers. BofA has confidence that Doximity’s Q4 “budget flush” will be significantly above Street expectations and that its revenue growth can potentially accelerate in 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Private Markets: Crusoe raises $1.375B at valuation above $10B
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Midday Fly By: Trump threatens China tariffs, Kalshi valued at $5B
- Align downgraded, NetEase upgraded: Wall Street’s top analyst calls
- Morning Movers: Applied Digital jumps on AI enthusiasm